Dow Jones
32.481,35 +236,77 (+0,73%) Nasdaq
11.840,18 +164,64 (+1,41%) Nikkei 225
26.945,67 -388,12 (-1,42%) EUR/USD
1,0768 +0,0042 (+0,3876%) BTC-EUR
26.155,75 +116,44 (+0,45%) CMC Crypto 200
613,05 +8,00 (+1,32%)
Arbutus Biopharma Corporation (ABUS)
| Chiusura precedente | 3,0200 |
| Aperto | 3,0550 |
| Denaro | 3,0100 x 900 |
| Lettera | 3,0200 x 2900 |
| Min-Max giorno | 2,9800 - 3,0800 |
| Intervallo di 52 settimane | 1,8500 - 3,2200 |
| Volume | |
| Media Volume | 963.255 |
| Capitalizzazione | 477,225M |
| Beta (5 anni mensile) | 2,21 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,0000 |
| Prossima data utili | 03 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,50 |
- GlobeNewswire
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161, Arbutus’ oral RNA destabilizer. AB
- GlobeNewswire
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preclinical data for AB-343, our novel oral SARS-CoV-2
- GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase 1 clinical trial for oral Mpro coronavirus candidate, AB-343, expected in the second half of 2023 Strengthened financial position – cash runway into Q4 2024 Conference Call and Webcast Today at 8:45 AM
